|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2010-12-16
|
|
pubmed:abstractText |
At 1 year, belatacept was associated with similar patient/graft survival, better renal function, and an improved cardiovascular/metabolic risk profile versus cyclosporine A (CsA) in the Belatacept Evaluation of Nephroprotection and Efficacy as Firstline Immunosuppression Trial (BENEFIT) and Belatacept Evaluation of Nephroprotection and Efficacy as Firstline Immunosuppression Trial-EXTended criteria donors (BENEFIT-EXT) studies. Acute rejection was more frequent with belatacept in BENEFIT. Posttransplant lymphoproliferative disorder (PTLD)--specifically central nervous system PTLD--was observed more frequently in belatacept-treated patients. This analysis assesses outcomes from BENEFIT and BENEFIT-EXT after 2 years of treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1534-6080
|
|
pubmed:author |
pubmed-author:BlockAlanA,
pubmed-author:BreshahanBarbaraB,
pubmed-author:CampistolJosep MJM,
pubmed-author:CharpentierBernardB,
pubmed-author:Di RussoGregoryG,
pubmed-author:FlormanSanderS,
pubmed-author:GargPushkalP,
pubmed-author:GrinyóJosepJ,
pubmed-author:KamarNassimN,
pubmed-author:LarsenChristian PCP,
pubmed-author:LinChen-ShengCS,
pubmed-author:Medina-PestanaJoséJ,
pubmed-author:RialMaria del CarmenMdel C,
pubmed-author:VanrenterghemYvesY,
pubmed-author:VincentiFlavioF
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
27
|
|
pubmed:volume |
90
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1528-35
|
|
pubmed:meshHeading |
pubmed-meshheading:21076381-Cyclosporine,
pubmed-meshheading:21076381-Follow-Up Studies,
pubmed-meshheading:21076381-Graft Survival,
pubmed-meshheading:21076381-Humans,
pubmed-meshheading:21076381-Immunoconjugates,
pubmed-meshheading:21076381-Immunosuppressive Agents,
pubmed-meshheading:21076381-Kidney Function Tests,
pubmed-meshheading:21076381-Kidney Transplantation,
pubmed-meshheading:21076381-Lymphoproliferative Disorders,
pubmed-meshheading:21076381-Postoperative Complications,
pubmed-meshheading:21076381-Risk Assessment,
pubmed-meshheading:21076381-Survival Rate,
pubmed-meshheading:21076381-Time Factors,
pubmed-meshheading:21076381-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.
|
|
pubmed:affiliation |
Emory Transplant Center and Department of Surgery, Emory University, Atlanta, GA, USA. clarsen@emory.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
